Skip to main content
Clinical Trials/CTIS2024-514148-99-00
CTIS2024-514148-99-00
Active, not recruiting
Phase 1

Markers of bonestatus in Diabetes Mellitus patients (type 1 and type 2) and the effect of antiresorptive treatment on glycemic markers

Aalborg University Hospital0 sites64 target enrollmentJune 7, 2024

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Aalborg University Hospital
Enrollment
64
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 7, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Type 1 diabetes / type 2 diabetes, Age \= 50 år, Same medical diabetes treatment the last six months (dose changes is allowed) and HbA1c changes on ± 1 in the same period, HbA1c level\= 6,7% in the last six months, Body mass index (BMI) between 19 og 35, DXA T\-score: \-3,5 til \-0,5

Exclusion Criteria

  • HbA1C \> 10%, Pregnancy, Metal implanted at ancle and wrist at all four ekstremities, Treatment by: Antiresorptives (inkl. HRT) or bone anabolic drugs, glucocorticoids, lithium and anticonvulsives, Patients with bone disease different from Osteoporosis, Vertebral fracture assessed by VFA, Patients with kidney disease defined by eGFR \< 50, Other significant medical disease in unstable phase (like cancer or hyperthyroidism), Heart failure in NYHA class IV, Previous allergic reactions to the trial drug, Previous allergic reactions to tetracyklin, Abnormities in esophagus and other factors, which may delay the transit time in the esophagus, Unable to stand or sit for 30 consecutive minutes, The investigator considers the patient unfit to participate, Patient with no understanding of the extent of the trial.

Outcomes

Primary Outcomes

Not specified

Similar Trials